CRISPR Therapeutics AG (NASDAQ:CRSP)’s traded shares stood at 1,738,519 during the last session, with the company’s beta value hitting 2.22. At the close of trading, the stock’s price was $125.89, to imply an increase of 0.77% or $0.96 in intraday trading. The CRSP share’s 52-week high remains $220.2, putting it -74.91% down since that peak but still an impressive +62.79% since price per share fell to its 52-week low of $46.84. The company has a valuation of $9.5 Billion, with an average of 1.77 Million shares in intraday trading volume over the past 10 days and average of 2.07 Million shares over the past 3 months.
Analysts have given a consensus recommendation of Overweight for CRISPR Therapeutics AG (CRSP), translating to a mean rating of 2.3. Of 21 analyst(s) looking at the stock, 2 analyst(s) give CRSP a Sell rating. None of those analysts rate the stock as Overweight while 6 advise Hold as 13 recommend it as a Buy. None analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$1.47.
After registering a 0.77% upside in the last session, CRISPR Therapeutics AG (CRSP) has traded green over the past five days. The stock hit a weekly high of $130.2 this Thursday, Apr 22, jumping 3.37% in its intraday price action. The 5-day price performance for the stock is 1.65%, and -5.35% over 30 days. With these gigs, the year-to-date price performance is -17.78%. Short interest in CRISPR Therapeutics AG (NASDAQ:CRSP) saw shorts transact 4.46 Million shares and set a 2.15 days time to cover.
Analysts on Wall Street suggest a consensus price target of $153.56, implying an increase of 21.98% to the stock’s current value. The extremes give us $45 and $210 for target low and target high price respectively. As such, CRSP has been trading 66.81% off suggested target high and -64.25% from its likely low.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
Looking at statistics comparing CRISPR Therapeutics AG share performance against respective industry, we note that the company has outperformed competitors. CRISPR Therapeutics AG (CRSP) shares are +17.99% up over the last 6 months, with its year-to-date growth rate higher than industry average at 10.4% against 8.3%. But the analysts are tempering their growth estimates for the 2021 fiscal year. Revenue is forecast to decline -27.8% this quarter before jumping 35.4% for the next one. The rating firms project that company’s revenue will grow 15059.9% compared to the previous financial year.
Revenue forecast for the current quarter as set by 16 analysts is $1.14 Million. Meanwhile, for the quarter ending June 01, 2021, a total of 16 analyst(s) estimate revenue growth to $57.4 Million. Earnings reports from the last fiscal year show that sales brought in $3.04 Million and $18.12 Million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to dip -62.5% before jumping 216.8% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings fell an estimated -52.5% for the past 5-year period. While 2021 is set for a -550.5% return in earnings, projections for the next 5 years are at 0% annually.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
CRISPR Therapeutics AG insiders hold 12.99% of total outstanding shares, with institutional holders owning 70.63% of the shares at 81.18% float percentage. In total, 527 institutions holds shares in the company, led by ARK Investment Management, LLC. As of Dec 30, 2020, the company held over 10.41 Million shares (or 13.81% of shares), all amounting to roughly $1.59 Billion.
The next major institution holding the largest number of shares is Capital International Investors with 7.43 Million shares, or about 9.85% of shares outstanding. As of the market price on Dec 30, 2020, these shares were worth $1.14 Billion.
We also have ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc as the top two Mutual Funds with the largest holdings of the CRISPR Therapeutics AG (CRSP) shares. Going by data provided on Mar 30, 2021, ARK ETF Tr-ARK Innovation ETF holds roughly 5,314,530 shares. This is just over 7.05% of the total shares, with a market valuation of $647.58 Million. Data from the same date shows that the other fund manager holds a little less at 2.1 Million, or 2.78% of the shares, all valued at about $255.64 Million.